
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc is positioned favorably due to its promising pipeline, particularly with icotrokinra, which shows significant dose-dependent improvements in clinical responses and remission rates over time, indicating its potential as a key player in the biopharmaceutical market. The company's strong business development track record and expected momentum from key catalysts leading into 2025 further enhance its growth prospects. Additionally, encouraging data on icotrokinra's efficacy and safety, particularly in challenging treatment areas, bolsters the outlook for successful market entry and widespread adoption once regulatory approvals are obtained.
Bears say
Protagonist Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns arising from ongoing clinical trials and the possibility of its strategic partners opting not to advance the development of key drug candidates like Icotrokinra (formerly JNJ-2113). Furthermore, the company is exposed to increased regulatory, competitive, and pricing risks, particularly in an evolving market that may affect the pricing and adoption of its therapeutic products. Additionally, there is concern over future cash requirements, which might necessitate dilution, further complicating the company’s financial position.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares